Shares of 4d Pharma PLC (LON: DDDD) rallied 9.1% after the live biotherapeutics company announced positive progress in the ongoing Phase I/II clinical trial of MRx0518 in combination with Merck’s Keytruda® on patients with advanced malignancies.
The company also reported positive progress in its pancreatic cancer study.
Most investors might have missed the importance of today’s announcements given that the trials were conducted on late-stage cancer patients who had taken inhibitor medications that were unsuccessful in treating their conditions.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
4D Pharma reported that it had treated 24 new patients in part B of its ongoing study from five US sites after completing part A of the study, which tested the toxicity levels in various dosing regimens of the drugs.
The trial has so far proven successful in patients with renal cell carcinomas (RCC), lung cancer and bladder cancer patients. Patients in part B trials have registered tumour reductions within the first nine weeks and bladder cancer patients showed the first signs of anti-tumour activity.
The company also reported that there were no notable side-effects on patients who were using its live biotherapeutics medications, which is a huge plus given the harsh side effects associated with most cancer treatments.
Investors were pleased with today’s data triggering a brief spike in 4D Pharma’s share price but it seems like the market is looking for bigger news to push the biotech company’s shares above their recent highs.
Some of the announcements that investors are awaiting include the completion of the reverse merger with Longevity Acquisition Corp (LOAC) to complete the company’s listing on the NASDAQ.
4D Pharma share price
4d Pharma shares surged 9.09% to trade at 126p having rallied from Tuesday’s closing price of 115.5p.
